These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 19037666)
1. Skin and oral lesions associated to imatinib mesylate therapy. Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666 [TBL] [Abstract][Full Text] [Related]
2. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia. Machaczka M; Gossart M Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191 [No Abstract] [Full Text] [Related]
3. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002 [TBL] [Abstract][Full Text] [Related]
4. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia. Novitzky-Basso I; Craddock C Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076 [No Abstract] [Full Text] [Related]
5. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Park SJ; Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS Acta Haematol; 2007; 118(4):219-21. PubMed ID: 18057867 [No Abstract] [Full Text] [Related]
7. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996 [TBL] [Abstract][Full Text] [Related]
8. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Hochhaus A Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968 [TBL] [Abstract][Full Text] [Related]
9. Initial treatment for patients with CML. Goldman JM Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231 [TBL] [Abstract][Full Text] [Related]
10. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085 [No Abstract] [Full Text] [Related]
11. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972 [TBL] [Abstract][Full Text] [Related]
14. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730 [TBL] [Abstract][Full Text] [Related]
15. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036 [TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate-induced pseudoporphyria in two children. Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470 [TBL] [Abstract][Full Text] [Related]
17. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. Kim DW; Tan EY; Jin Y; Park S; Hayes M; Demirhan E; Schran H; Wang Y Br J Clin Pharmacol; 2011 Feb; 71(2):199-206. PubMed ID: 21219400 [TBL] [Abstract][Full Text] [Related]